- Home
- PRLD vs PLBY Comparison
PRLD vs PLBY Comparison
Compare PRLD & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- PLBY
- Stock Information
- Founded
- PRLD 2016
- PLBY 1953
- Country
- PRLD United States
- PLBY United States
- Employees
- PRLD N/A
- PLBY N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- PLBY Recreational Games/Products/Toys
- Sector
- PRLD Health Care
- PLBY Consumer Discretionary
- Exchange
- PRLD Nasdaq
- PLBY Nasdaq
- Market Cap
- PRLD 63.3M
- PLBY 53.2M
- IPO Year
- PRLD 2020
- PLBY N/A
- Fundamental
- Price
- PRLD $1.04
- PLBY $1.16
- Analyst Decision
- PRLD Buy
- PLBY Buy
- Analyst Count
- PRLD 3
- PLBY 2
- Target Price
- PRLD $5.33
- PLBY $2.35
- AVG Volume (30 Days)
- PRLD 408.0K
- PLBY 8.4M
- Earning Date
- PRLD 11-06-2024
- PLBY 11-12-2024
- Dividend Yield
- PRLD N/A
- PLBY N/A
- EPS Growth
- PRLD N/A
- PLBY N/A
- EPS
- PRLD N/A
- PLBY N/A
- Revenue
- PRLD $3,000,000.00
- PLBY $72,188,000.00
- Revenue This Year
- PRLD N/A
- PLBY N/A
- Revenue Next Year
- PRLD N/A
- PLBY N/A
- P/E Ratio
- PRLD N/A
- PLBY N/A
- Revenue Growth
- PRLD N/A
- PLBY N/A
- 52 Week Low
- PRLD $1.00
- PLBY $0.44
- 52 Week High
- PRLD $6.80
- PLBY $1.55
- Technical
- Relative Strength Index (RSI)
- PRLD 21.69
- PLBY 59.27
- Support Level
- PRLD $1.14
- PLBY $0.85
- Resistance Level
- PRLD $1.36
- PLBY $1.14
- Average True Range (ATR)
- PRLD 0.11
- PLBY 0.19
- MACD
- PRLD 0.03
- PLBY -0.00
- Stochastic Oscillator
- PRLD 7.53
- PLBY 53.85
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.